Comparing PFE's and BMY's Immunology Drugs - Market Realist

Comparing PFE's and BMY's Immunology Drugs  Market Realist

Pfizer's (PFE) commercialized JAK (Janus kinase) inhibitor, Xeljanz, is approved for treating rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.